ArriVent BioPharma, Inc.
AVBP · Pharmaceutical Preparations · 46.6M shares · +1370%/yr ↑ dilution · EDGAR filings ↗
Reference price $23.37 · est. market cap ~$1.1B — last insider sale, 2025-12-10 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — oncology clinical, very cash-rich.
Strengths
- Liquidity — current ratio 12.8 (86th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +1370%/yr over 1y (dilution, book value/share -92%)
- Strong balance sheetStrong balance sheet — $313M cash & investments
- Notable holderHeld by 4 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
- AccumulatingInstitutional holders rose 9→10 QoQ (2025-12-31→2026-03-31)
Key metrics
Return on equity
-54.1%
Return on assets
-49.9%
Current ratio
12.8×
EBITDA
-$181M
Tangible book value
$307M
Cash & investments
$313M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. | Sell | 556K | $23.37 |
| 2025-07-11 | LaChapelle Robin | Option exercise | 2.0K | $2.28 |
| 2025-07-11 | LaChapelle Robin | Option exercise | 2.6K | $2.28 |
| 2025-07-11 | LaChapelle Robin | Option exercise | 6.5K | $2.28 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07066657 ↗ | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer | PHASE1 | Recruiting | 2029-05-01 |
| NCT07185997 ↗ | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer | PHASE3 | Recruiting | 2029-02-01 |
| NCT05607550 ↗ | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | PHASE3 | Active Not Recruiting | 2025-08-15 |
| NCT05364073 ↗ | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer | PHASE1 | Active Not Recruiting | 2025-06-03 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-22 | 2026-06-18 | 0001104659-26-076352 ↗ |
| 8-K | 2026-05-11 | 2026-05-11 | 0001104659-26-058706 ↗ |
| 10-Q | 2026-05-11 | 2026-03-31 | 0001104659-26-058650 ↗ |
| 8-K | 2026-05-11 | 2026-05-11 | 0001104659-26-058638 ↗ |
| 8-K | 2026-03-17 | 2026-03-17 | 0001104659-26-029588 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001104659-26-024112 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001104659-26-024127 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001104659-25-108847 ↗ |
| 8-K | 2025-11-10 | 2025-11-10 | 0001104659-25-108839 ↗ |
| 8-K | 2025-09-09 | 2025-09-09 | 0001558370-25-011954 ↗ |
| 8-K | 2025-08-11 | 2025-08-11 | 0001558370-25-010974 ↗ |
| 10-Q | 2025-08-11 | 2025-06-30 | 0001558370-25-010975 ↗ |